Humacyte (NASDAQ:HUMA) Stock Price Target Raised at Barclays

Humacyte (NASDAQ:HUMA) had its price objective raised by Barclays from $0.50 to $0.60 in a research report report published on Wednesday morning,Benzinga reports. The firm currently has an equal weight rating on the stock.

Other research analysts have also issued research reports about the company. Wall Street Zen lowered Humacyte from a “sell” rating to a “strong sell” rating in a research report on Saturday, August 15th. Weiss Ratings reissued a “sell (e+)” rating on shares of Humacyte in a report on Friday, October 2nd. Williams Trading set a $1.00 target price on shares of Humacyte in a research report on Friday, October 16th. HC Wainwright reaffirmed a “buy” rating on shares of Humacyte in a report on Friday, October 16th. Finally, Benchmark cut their target price on shares of Humacyte from $2.00 to $1.00 and set a “speculative buy” rating on the stock in a report on Thursday, August 13th. Six investment analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat, Humacyte presently has an average rating of “Moderate Buy” and an average target price of $4.98.

Humacyte Stock Performance

NASDAQ HUMA opened at $0.59 on Wednesday. The company has a debt-to-equity ratio of 2.07, a quick ratio of 5.74 and a current ratio of 6.21. Humacyte has a 1 year low of $0.34 and a 1 year high of $1.52. The company has a fifty day moving average of $0.49 and a two-hundred day moving average of $0.78.

Humacyte (NASDAQ:HUMA) last posted its earnings results on Wednesday, August 12th. The company reported ($0.16) EPS for the quarter, missing analysts’ consensus estimates of ($0.11) by ($0.05). The firm had revenue of $0.41 million for the quarter, compared to analyst estimates of $1.04 million. Humacyte had a negative return on equity of 640.19% and a negative net margin of 3,955.05%. On average, equities analysts anticipate that Humacyte will post -0.40 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

Institutional investors have recently modified their holdings of the stock. Beacon Pointe Advisors LLC purchased a new position in Humacyte in the 2nd quarter valued at $28,000. Bank of New York Mellon Corp acquired a new stake in shares of Humacyte in the 2nd quarter worth $44,000. Sei Investments Co. purchased a new stake in shares of Humacyte in the first quarter valued at about $56,000. Miramontes Capital LLC purchased a new stake in shares of Humacyte in the second quarter valued at about $85,000. Finally, LaSalle St. Investment Advisors LLC purchased a new stake in shares of Humacyte in the second quarter valued at about $89,000. Institutional investors and hedge funds own 44.71% of the company’s stock.

Top Humacyte Stories

These are some of the HUMA stories that stood out recently:

• Positive Sentiment: Humacyte plans five presentations at the November 17–21 VEITHsymposium, including interim Phase 3 results in women receiving hemodialysis and combined outcomes from three dialysis-access trials. The company also plans to submit a supplemental BLA for hemodialysis access in November, creating a near-term clinical and regulatory catalyst. Humacyte VEITHsymposium announcement
• Neutral Sentiment: Barclays raised its HUMA price target from $0.50 to $0.60 but maintained an “equal weight” rating. At the cited $0.59 share price, the new target suggests limited upside, tempering the benefit of the increase. Barclays rating information
• Negative Sentiment: Symvess carries a boxed warning for potentially life-threatening graft failure, along with warnings including rupture, anastomotic failure and thrombosis. These safety risks may weigh on adoption; the newly announced presentations have not yet provided their results.

Humacyte Company Profile

Humacyte, Inc. is a biotechnology company developing bioengineered human tissues for use in regenerative medicine and vascular repair. The company’s platform is designed to create implantable, off-the-shelf tissues that can be stored and used when needed without requiring the collection of tissue from the patient. Its primary product is SYMVESS, an acellular tissue-engineered vessel intended to replace or repair damaged blood vessels. In December 2024, the U.S. Food and Drug Administration approved SYMVESS for use in the urgent treatment of extremity arterial injuries when emergency vascular reconstruction is required.